Southeast Asia has roughly 350 million women, and they make most of the household’s health decisions. That alone makes women’s health a large consumer market rather than a vertical. But market size tells you little about behaviour, and behaviour is where the interesting signal is. FemTech Association Asia’s 2026 research across six markets, run with Milieu Insight, is the clearest read we have on how women in this region actually approach their health. A few patterns are worth pulling out.

Usage runs well ahead of awareness

Most women in these markets don’t recognise the word “femtech,” but a clear majority already use women’s health products and services, and a majority of current non-users say they intend to start within months.

The numbers bear this out. In the Philippines, only 31 per cent of women recognise the term “femtech”, yet 65 per cent already use these tools, and 57 per cent of non-users plan to try them within six months. Indonesia shows the same gap: 29 per cent recognise the term, 55 per cent are already users, and 69 per cent of non-users intend to start within six months. In both markets, adoption is running well ahead of awareness, according to the FemTech Association Asia and Milieu Insight consumer survey.

The practical implication: the constraint on this market is not demand or education. Campaigns built around “introducing women to femtech” are solving a problem that the data says is already solved. The open question is supply: whether what’s on offer is good enough to convert intent that already exists.

Also Read: How Singapore became a leading femtech startup hub in SEA

Adoption concentrates at the consumer layer, not the clinical one

Familiarity and usage both cluster in the same place: menstrual products and cycle-tracking apps. These share a trait; a woman can research, buy, or download them without involving a clinician. Categories that require a clinical interaction (screening, diagnostics, specialist consults) show far thinner adoption.

This isn’t random. It maps onto how women select among options in the first place. The dominant decision drivers are ease of use, convenience, and cost. These are criteria you apply to a consumer product, not the criteria you apply to a course of treatment. Read that way, women aren’t under-prioritising their health; they’re optimising for access against health systems that are expensive and inconvenient, where out-of-pocket spending runs around 40 per cent of total health expenditure in markets like the Philippines. The phone wins because it clears those hurdles. A clinic usually doesn’t.

The information layer has moved; the care layer hasn’t

A related pattern: women increasingly source health information from screens rather than clinicians. In several markets, social media is a leading channel even for something as consequential as menopause. With daily time online among the highest in the world here, that migration is unsurprising.

So the typical path now looks like: notice something, research it privately online, track it in an app, and then stall. The information and tracking layers have fully digitised. The step that turns a signal into care has not. A tracker can tell a woman her cycle has been irregular for months; it generally can’t put her in front of the OB-GYN or into the PCOS screening that irregularity might warrant. The product delivers the insight and leaves her at the threshold of the clinical system.

The useful way to frame the next phase of femtech is not better measurement. It’s conversion: the rate at which an in-app signal becomes an actual consultation or screening.

Also Read: Overcoming advertising woes and other challenges for the femtech industry

Discretion is a design constraint, not a preference

One more data point explains why that conversion is hard to engineer. Across the six markets, roughly half of women report worrying about judgement or shame when discussing their health openly. That’s a large and measurable friction, and it’s a plausible reason women start privately on a device rather than in a clinic.

The implication for anyone building the bridge to care: discretion can’t be dropped at the handoff. A flow that moves a woman from a private concern to a visible, exposed clinical interaction will lose her at the seam. The products most likely to convert are the ones that preserve privacy end to end, from the moment of concern to the point of screening or consult.

What the pattern implies for builders and investors

Put the findings together and a fairly specific picture emerges. Demand exists and is growing. It concentrates where friction is lowest, consumer products and tracking, and thins out wherever a clinical step is required. Women choose on convenience and cost, inform themselves online, and prize discretion throughout.

The commercial reading is that the value isn’t in adding another measurement tool to a layer women already use. It’s in building the connective tissue the current products lack: the part that takes an engaged user from tracking to screening to treatment, at consumer-grade convenience and cost, without sacrificing privacy. That’s harder to build than a tracker, which is precisely why it’s where the defensibility, and the unmet demand, sits. For investors, the mispricing is the same point from the other side: a market that serves half the population through the channel that half already uses has been treated as niche largely because it was labelled that way.

The behaviour is already clear. The product question is whether anyone will build for how women actually use femtech, rather than for how the health system wishes they would.

Consumer findings referenced here are from FemTech Association Asia’s 2026 Southeast Asia research series, produced with Milieu Insight. Hati Health is a member of FemTech Association Asia.

—

The post Why femtech adoption in Southeast Asia stops at the clinic door appeared first on e27.